InflaRx (NASDAQ:IFRX) Announces Earnings Results

InflaRx (NASDAQ:IFRX) released its quarterly earnings data on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.04), Zacks reports.

InflaRx Price Performance

Shares of NASDAQ IFRX traded up $0.12 during midday trading on Friday, hitting $1.84. The stock had a trading volume of 1,167,412 shares, compared to its average volume of 890,553. The firm has a market cap of $133.01 million, a P/E ratio of -3.17 and a beta of 2.48. InflaRx has a fifty-two week low of $0.78 and a fifty-two week high of $2.95. The company’s 50-day simple moving average is $1.89 and its 200 day simple moving average is $1.53.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Raymond James Financial raised shares of InflaRx from an “outperform” rating to a “strong-buy” rating and upped their price objective for the stock from $7.00 to $9.00 in a research note on Wednesday, May 13th. Zacks Research upgraded shares of InflaRx from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 27th. Cantor Fitzgerald boosted their target price on InflaRx from $4.00 to $6.00 and gave the stock an “overweight” rating in a report on Friday. Guggenheim restated a “buy” rating and set a $14.00 price target on shares of InflaRx in a research report on Tuesday, April 21st. Finally, Oppenheimer started coverage on InflaRx in a report on Friday, April 24th. They set an “outperform” rating and a $5.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $7.33.

Hedge Funds Weigh In On InflaRx

Several hedge funds have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC raised its holdings in InflaRx by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after purchasing an additional 7,616 shares during the last quarter. HRT Financial LP bought a new position in shares of InflaRx in the 4th quarter valued at about $47,000. Insigneo Advisory Services LLC bought a new position in shares of InflaRx in the 4th quarter valued at about $61,000. Quadrature Capital Ltd acquired a new stake in shares of InflaRx during the 4th quarter worth approximately $104,000. Finally, XTX Topco Ltd acquired a new stake in shares of InflaRx during the 4th quarter worth approximately $135,000. Institutional investors own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.